Schmidbauer C, Schwarz M, Schutz A, Schubert R, et al. Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy. PLoS One 2021;16:e0252274.
PMID: 34086708